SOURCE: Medivation

Medivation

May 11, 2016 07:35 ET

Medivation Receives Prestigious Award From American Urological Association (AUA)

Presented During 2016 Annual Scientific Meeting

SAN FRANCISCO, CA--(Marketwired - May 11, 2016) - Medivation Inc. (NASDAQ: MDVN) announced today that it is the recipient of the 2016 Health Science Award from The American Urological Association (AUA) for outstanding support of physician and patient education in prostate cancer. The Health Science Award is presented to the company that best supports the AUA's mission to promote the highest standards of urological clinical care through education, research and formulation of healthcare policy. The award was received last night at the Annual Awards Banquet during the 2016 Annual Scientific Meeting of the AUA in San Diego.

Medivation sponsors, supports, develops, and contributes to physician and patient education in prostate cancer through a variety of programs, materials, and national, regional and local events. This educational activity is aimed at expanding the understanding and awareness of advanced prostate cancer. In addition to its support of several programs conducted in cooperation with the AUA, such as the annual scientific meeting, as well as its partnership with the AUA's Urology Care Foundation, Medivation is active with continuing medical education for healthcare professionals and deeply engaged with the prostate cancer patient advocacy community.

"Medivation has been a committed partner to and an ardent supporter of the AUA and the Urology Care Foundation, helping us increase awareness about prostate cancer through a variety of forums, as well as contributing greatly to a number of patient education efforts," said AUA Executive Vice President, Development and Publications, Kevin A. Wohlfort. "It's been three years since we've recognized an industry partner for their contributions, and we are proud to present Medivation with the Health Science Award to honor its ongoing commitment to helping patients and supporting the prostate cancer community."

In addition to its support of many physician education efforts, Medivation is involved with the prostate cancer patient advocacy community through a variety of activities such as teleconferences, webcasts, helplines, online patient support services, local community outreach, newsletters, radio programming, support groups, cancer resource directories, patient conferences, walks and runs, that are aimed at increasing awareness and empowerment among patients and caregivers.

"Like the AUA, Medivation is committed to advancing education and research, so we are honored to be acknowledged by such an outstanding organization for the work we are doing to advance the understanding around prostate cancer," said David Hung, M.D., founder, president & chief executive officer of Medivation. "We feel it is part of our mission and it is our privilege to give back to the community by supporting the informational needs of clinicians, patients and caregivers."

About Medivation, Inc.
Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit www.medivation.com.

Contact Information

  • Contacts:

    Investors
    Anne Bowdidge
    (650) 218-6900

    Media
    Samina Bari
    (415) 275-5893